Abstract
The present study is related to a commercially practicable new synthetic process for production of teneligliptin hydrobromide hydrate (1), a dipeptidyl peptidase-4 (DPP-4) inhibitor. Key strategies in the new process include preparation and isolation of new intermediates such as a better reactive nosyl derivative (3c) of l-proline methyl ester (2), its stereoselective substituted intermediate (5) with 1-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazine (4) through SN2-type nucleophilic substitution, and isolation of carboxylic acid derivative 6 by deesterification of intermediate 5. The reaction conditions for preparation of new intermediates, and the additionally used coupling reaction for amidation and deprotection of N-Boc were optimized with control of impurities to improve the quality of drug molecule 1 with good yield. The developed synthetic strategy offers significant advantages over existing synthetic approaches, avoiding use of expensive reagents, long time consumption, and laborious procedures involving isolation of intermediates. The developed process for drug molecule 1, achieving overall yield of 37–39% over six sequential chemical transformations, enables rapid delivery of multi-kilogram quantities of the desired active pharmaceutical ingredient (API), meeting stringent purity requirements.
Graphical Abstract
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
M. Kishimoto, Diabetes Metab. Syndr. Obes. 6, 187–195 (2013)
J.A. Lovshin, D.J. Drucker, Nat. Rev. Endocrinol. 5(5), 262–269 (2009)
J.J. Neumiller, Clin. Ther. 33(5), 528–576 (2011)
J. Bronson, A. Black, T.G. Murali Dhar, B.A. Ellsworth, J.A. Merritt, Annu. Rep. Med. Chem. 48, 471–546 (2013)
M. Goda, T. Kadowaki, Drugs Today (Barc) 49(10), 615–629 (2013)
S. Tanaka, K. Suzuki, C. Aoki, M. Niitani, K. Kato, T. Tomotsune, Y. Aso, Diabetes Technol. Ther. 16(12), 840–845 (2014)
H. Kitajima, H. Sakashita, F. Akahoshi, Y. Hayashi, US Patent 7,074,794 B2 (2006)
ICH Q3C(R5) Impurities: guidelines for residual solvents, international conference on harmonization of technical requirements for registration of pharmaceuticals for human use (ICH): Geneva, Switzerland (2011)
T. Yoshida, H. Sakashita, N. Ueda, S. Kirihara, S. Uemori, R. Tsutsumiuchi, F. Akahoshi, US Patent 2011/0282058A1 (2011)
F. Akahoshi, K. Shinji, WO Patent 2012165547 A1 (2012)
M.K. Suresh, P.K. Bipin, V.K. Ramachandran, P.P. Jayant, Y. Venkataramana Reddy, N.B. Shailendra, P.C. Uddhav, D.P. Ulhas, B.B. Shekhar, WO Patent 2014041560 A2 (2014)
T. Wang, J.F. Kadow, Z. Zhang, Z. Yin, N.A. Meanwell, A. Regueiro-Ren, J. Swidorski, Y. Han, D.J. Carini, L.G. Hamann, US Patent 2008/0139572 A1 (2008)
S. Warren, P. Wyatt, Organic Synthesis: The Disconnection Approach (Wiley, New York, 2008)
J. Seo, P. Martasek, L.J. Roman, R.B. Silverman, Bioorg. Med. Chem. 15(5), 1928–1938 (2007)
F. Diaba, E. Ricou, J. Bonjoch, Tetrahedron Asymmetry 17(9), 1437–1443 (2006)
T. Hwang, H. Kim, K.I. Lee, Bull. Korean Chem. Soc. 8, 2128 (2015)
A. Fisher, A. Mann, V. Verma, N. Thomas, R.K. Mishra, R.L. Johnson, J. Med. Chem. 49(1), 307–317 (2006)
H. Marusawa, H. Setoi, A. Sawada, A. Kuroda, J. Seki, Y. Motoyama, H. Tanaka, Bioorg. Med. Chem. 10(5), 1399–1415 (2002)
K.I. Tanaka, H. Sawanishi, Tetrahedron Asymmetry 9(1), 71–77 (1998)
C. Lerner, R. Siegrist, E. Schweizer, F. Diederich, V. Gramlich, R. Jakob-Roetne, G. Zurcher, E. Borroni, Helv. Chim. Acta 86(4), 1045–1061 (2003)
I.F. Pickersgill, H. Rapoport, J. Org. Chem. 65(3), 4048–4057 (2000)
D. Lafrance, S. Caron, Org. Process Res. Dev. 16(3), 409–414 (2012)
C.J. Barnett, B. Huff, M.E. Kobierski, M. Letourneau, T.M. Wilson, J. Org. Chem. 69(22), 7653–7660 (2004)
S.K. Thompson, S.M. Halbert, M.J. Bossard, T.A. Tomaszek, M.A. Levy, B. Zhao, W.W. Smith, S.S. Abdel-Meguid, C.A. Janson, K.J. Dalessio, M.S. Mcqueney, B.Y. Amegadzie, C.R. Hanning, R.L. Desjarlais, J. Briand, S.K. Sarkar, M.J. Huddleston, C.F. Ijames, S.A. Carr, K.T. Garnes, A. Shu, J.R. Heys, J. Bradbeer, D. Zembryki, L. Rykaczewski, I.E. James, M.W. Lark, F.H. Drake, M. Gowen, J.H. Gleason, D.F. Veber, Proc. Natl. Acad. Sci. USA 94(26), 14249–14254 (1997)
I.G. Boutselis, X. Yu, Z.Y. Zhang, R.F. Borch, J. Med. Chem. 50(4), 856–864 (2007)
T. Yoshida, F. Akahoshi, H. Sakashita, H. Kitajima, M. Nakamura, S. Sonda, M. Takeuchi, Y. Tanaka, T. Ueda, S. Sekiguchi, T. Ishige, K. Shima, M. Nabeno, Y. Abe, J. Anabuki, A. Soeiima, K. Yoshida, Y. Takashina, S. Ishii, S. Kiuchi, S. Fukuda, R. Tsutsumiuchi, K. Kosaka, T. Murozono, Y. Nakamaru, H. Utsumi, N. Masutomi, H. Kishida, I. Miyaguchi, Y. Hayashi, Bioorg. Med. Chem. 20(19), 5705–5719 (2012)
Acknowledgements
The authors greatly appreciate financial support of this work from Micro Labs Ltd., API Division Centre, ML-27, Bangalore. We thank our group colleagues for their appreciated contributions. We also wish to thank Ajay Thakur, Dr. Anamica, Sathish, Rajiv, Naresh, and Ridhima Kochar for their valuable analytical support and cooperation.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Kumar, N., Devineni, S.R., Aggile, K. et al. Facile new industrial process for synthesis of teneligliptin through new intermediates and its optimization with control of impurities. Res Chem Intermed 44, 567–584 (2018). https://doi.org/10.1007/s11164-017-3120-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11164-017-3120-3